Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Xeris Pharmaceuticals Enters Collaboration Agreement With Merck; Financial Terms Not Disclosed

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a
byBill Haddad
October 25, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck , with an option to license Xeris’ suspension-based formulation technology, XeriJect™, for use with undisclosed monoclonal antibodies (mAbs) for the purpose of engineering ultra-high concentration, ready-to-use formulations. Terms of the agreement were not disclosed.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Supreme Court Blocks Biden Mandate On COVID-19 Vaccinations

By Phil Hall
Today, 8:32 PM
The U.S. Supreme Court has blocked the Biden administration’s mandate that would require private companies from enacting vaccine-or-test requirements on its workforce, but it allowed a similar mandate by the U.S. Department of Health and Human Services (HHS) to go into effect at medical facilities that take Medicare or Medicaid payments.

SPY